Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease after study entry and before tisagenlecleucel infusion. Here,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Bishop, Michael R., Maziarz, Richard T., Waller, Edmund K., Jäger, Ulrich, Westin, Jason R., McGuirk, Joseph P., Fleury, Isabelle, Holte, Harald, Borchmann, Peter, del Corral, Christopher, Tiwari, Ranjan, Anak, Özlem, Awasthi, Rakesh, Pacaud, Lida, Romanov, Vadim V., Schuster, Stephen J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650727/
https://ncbi.nlm.nih.gov/pubmed/31332046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados